A study to investigate the effect of lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) (ACCLAIM-Lp(a)) (NCT06292013)

Educational Partners and Supporters

Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum. (Founding Partner)